These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38535322)

  • 1. Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis.
    Kleinjan JP; Blom J; van Beek AP; Bouma HR; van Dijk PR
    Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
    Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
    Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
    Chaudhry A; Roels C; Lee J
    Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
    Laursen HVB; Røikjer JB; Dal J; Jensen MH
    Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.
    Cohen B; Harris YT; Schulman-Rosenbaum R
    Endocr Pract; 2024 Apr; 30(4):402-408. PubMed ID: 38081453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
    Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
    Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
    Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
    Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors.
    Almazrouei R; Afandi B; AlKindi F; Govender R; Al-Shamsi S
    Clin Med Insights Endocrinol Diabetes; 2023; 16():11795514231153717. PubMed ID: 36844982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series.
    Meier M; Ansong B; Awobusuyi D; Lee-Oyagha R; Lopez S
    J Pharm Pract; 2024 Aug; ():8971900241273169. PubMed ID: 39123293
    [No Abstract]   [Full Text] [Related]  

  • 14. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
    Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
    AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
    Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression.
    Sridharan K; Sivaramakrishnan G
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541972
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
    Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
    Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.